Abstract: . . .  unfractionated heparin in the initial treatment advantages of subcutaneous once or twice daily dosage without monitoring has made it possible to treat patients in an out-patient setting. But pregnant state is a contraindication for such treatment 29 . What is the role of thrombolytics in pregnancy? No controlled trials on the safety and efficacy of thrombolytics in pregnant patients have been done. Because of the risks of maternal  . . .
. . .  decreased fibrinolysis and reduced levels of the natural anticoagulant, protein S contribute to this state of hypercoagulability during pregnancy 6,7 . Venous stasis resulting from pressure of the gravid uterus on inferior vena cava and decreased venous tone are further predisposing factors present in all pregnant women. In an USG study of gestational changes of the venous system of the lower extremities, Macklon and associates  . . .
. . .  fibrinolysis and reduced levels of the natural anticoagulant, protein S contribute to this state of hypercoagulability during pregnancy 6,7 . Venous stasis resulting from pressure of the gravid uterus on inferior vena cava and decreased venous tone are further predisposing factors present in all pregnant women. In an USG study of gestational changes of the venous system of the lower extremities, Macklon and associates 8  . . .
. . .  fibrinolysis and reduced levels of the natural anticoagulant, protein S contribute to this state of hypercoagulability during pregnancy 6,7 . Venous stasis resulting from pressure of the gravid uterus on inferior vena cava and decreased venous tone are further predisposing factors present in all pregnant women. In an USG study of gestational changes of the venous system of the lower extremities, Macklon and associates 8 documented . . .
. . .  29. Lindmarker P. Can all patients with deep vein thrombosis receive LMWH in an outpatient setting? Haemostasis 1999; 29 (Suppl 1): 84-8. 30. Tengbor L, Brqvist D, Matgsch R et al . Recurrent thromboembolism in pregnancy and puerperium. Am J Obstet Gynaecol 1985; 28: 107-18.  . . .
. . .  activation of the coagulation cascade during subsequent pregnancy. Prophylactic doses of UFH and LMWH : Higher doses are needed for effective prophylaxis during pregnancy to offset the characteristic increase in plasma volume, renal clearance, and blood levels of coagulation factors and to counteract the alterations in metabolism of heparin that occurs during pregnancy. Subcutaneous heparin 7,500 to 10,000 U should be administered twice daily. Prophylactic . . .
--3000,6,250,3270,38130